1 – 20 of 20
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
2024) In Molecular Oncology(
- Contribution to journal › Article
- 2023
-
Mark
CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer
(
- Contribution to journal › Article
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
- 2021
-
Mark
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
(
- Contribution to journal › Article
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2018
-
Mark
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
(
- Contribution to journal › Article
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
-
Mark
Immune gene expression and response to chemotherapy in advanced breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
(
- Contribution to journal › Article
-
Mark
PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients
(
- Contribution to journal › Article
-
Mark
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
(
- Contribution to journal › Article
- 2016
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
(
- Contribution to journal › Article
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer
(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study
(
- Contribution to journal › Article
-
Mark
Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
(
- Contribution to journal › Article
-
Mark
When Is the Deep Inferior Epigastric Artery Flap Indicated for Breast Reconstruction in Patients not Treated With Radiotherapy?
(
- Contribution to journal › Article
- 2013
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
-
Mark
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
(
- Contribution to journal › Article
- 2009
-
Mark
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden.
(
- Contribution to journal › Article